Global Central Nervous System (CNS) Biomarkers Market Research, 2014-2020
MARKET INSIGHTS:
The Global Central Nervous System (CNS) Biomarkers Market is expected to grow at a CAGR 18% during 2015-2020. The Global CNS Biomarkers Market is growing at a modest rate due to development in imaging system, proteomics & genomics and rise in demand for CNS biomarkers across the globe. Huge demand is created by growing life style oriented diseases such as CVD, CHD, Stroke, Cancer and other heart diseases across the globe. Favorable government regulations and policies are driving the market. Successful clinical trials and investment in R&D is creating huge scope in Global CNS Biomarkers Market. Global rise in adoption of CNS biomarkers in developed and emerging economies has also boosted the market. Global CNS Biomarkers Market by applications such as personalized medicine, disease risk assessment, diagnostic development, drug discovery and development are widely adopted across the globe. Personalized medicines and drug discovery & development has significant contribution in the growth of CNS Biomarker Market.
Global CNS Biomarkers Market by type such as safety biomarker, efficacy biomarker, predictive biomarker and prognostic biomarker are generating considerable revenues across the globe. Success of clinical trials and personalized medicines are boosting the market. It enables the Global As a result CNS Biomarkers key players are focusing more into R&D and clinical trials of Biomarkers. Untapped APAC region is considered to be full of opportunity due to rising demand of CNS Biomarker in emerging economies such as India, China, Japan and Korea.
GEOGRAPHICAL INSIGHTS
North America contributes highest in Global CNS Biomarker Market followed by Europe. The key drivers of the significant contribution of North America is the rising adoption of CNS biomarkers due to rise in life style oriented diseases such as Cancer, CVD, CHD, Stroke and other heart diseases. Emerging economies such as China, India, Japan and Korea has huge customer base and improved healthcare spending which are expected to create huge opportunity for Global CNS Biomarker Market. Improved standard of living, infrastructural development and favorable government policies are other factors that are driving the APAC market. The report includes detailed Market Overview, Market Determinants, Company Profiling, Sector Analysis, Market Segmentation, Geographical Analysis, Pipeline Analysis, Patent Analysis, Strategic Recommendations, Key Company Analysis, GAP Analysis, Key Findings, Market Estimations, Market Insights, Analyst Insights and predictive analysis of the market.Competitive Insights:
The Global CNS Biomarkers Market companies includes: Thermo fisher scientific, Abiant Inc, Enzo biochem inc, EKF diagnostics holdings Inc, Acumen pharmaceuticals Inc, Abastar MDX Inc, Adlyfe Inc, Alseres pharmaceuticals Inc, Apitope international, Aposense, Avid radiopharmaceuticals Inc, Banyan biomarkers, Diagenic ASA, Applied neurosolutions Inc, Avacta group plc, Merc & co. Inc and Exonhit therapeutics. CNS Biomarker companies are constantly focusing on R&D, partnerships, M&A, innovation and technological advancement.
MARKET SEGMENTATION:
Global CNS Biomarkers Market is segmented on the basis of application, type, end user and geography. Global CNS Biomarkers Market by application which includes diagnostic development, drug discovery and development, personalized medicine, disease risk assessment are in huge demand and contributing highest in the growth of CNS biomarkers market.
The Global Central Nervous System (CNS) Biomarkers Market is expected to grow at a CAGR 18% during 2015-2020. The Global CNS Biomarkers Market is growing at a modest rate due to development in imaging system, proteomics & genomics and rise in demand for CNS biomarkers across the globe. Huge demand is created by growing life style oriented diseases such as CVD, CHD, Stroke, Cancer and other heart diseases across the globe. Favorable government regulations and policies are driving the market. Successful clinical trials and investment in R&D is creating huge scope in Global CNS Biomarkers Market. Global rise in adoption of CNS biomarkers in developed and emerging economies has also boosted the market. Global CNS Biomarkers Market by applications such as personalized medicine, disease risk assessment, diagnostic development, drug discovery and development are widely adopted across the globe. Personalized medicines and drug discovery & development has significant contribution in the growth of CNS Biomarker Market.
Global CNS Biomarkers Market by type such as safety biomarker, efficacy biomarker, predictive biomarker and prognostic biomarker are generating considerable revenues across the globe. Success of clinical trials and personalized medicines are boosting the market. It enables the Global As a result CNS Biomarkers key players are focusing more into R&D and clinical trials of Biomarkers. Untapped APAC region is considered to be full of opportunity due to rising demand of CNS Biomarker in emerging economies such as India, China, Japan and Korea.
GEOGRAPHICAL INSIGHTS
North America contributes highest in Global CNS Biomarker Market followed by Europe. The key drivers of the significant contribution of North America is the rising adoption of CNS biomarkers due to rise in life style oriented diseases such as Cancer, CVD, CHD, Stroke and other heart diseases. Emerging economies such as China, India, Japan and Korea has huge customer base and improved healthcare spending which are expected to create huge opportunity for Global CNS Biomarker Market. Improved standard of living, infrastructural development and favorable government policies are other factors that are driving the APAC market. The report includes detailed Market Overview, Market Determinants, Company Profiling, Sector Analysis, Market Segmentation, Geographical Analysis, Pipeline Analysis, Patent Analysis, Strategic Recommendations, Key Company Analysis, GAP Analysis, Key Findings, Market Estimations, Market Insights, Analyst Insights and predictive analysis of the market.Competitive Insights:
The Global CNS Biomarkers Market companies includes: Thermo fisher scientific, Abiant Inc, Enzo biochem inc, EKF diagnostics holdings Inc, Acumen pharmaceuticals Inc, Abastar MDX Inc, Adlyfe Inc, Alseres pharmaceuticals Inc, Apitope international, Aposense, Avid radiopharmaceuticals Inc, Banyan biomarkers, Diagenic ASA, Applied neurosolutions Inc, Avacta group plc, Merc & co. Inc and Exonhit therapeutics. CNS Biomarker companies are constantly focusing on R&D, partnerships, M&A, innovation and technological advancement.
MARKET SEGMENTATION:
Global CNS Biomarkers Market is segmented on the basis of application, type, end user and geography. Global CNS Biomarkers Market by application which includes diagnostic development, drug discovery and development, personalized medicine, disease risk assessment are in huge demand and contributing highest in the growth of CNS biomarkers market.
REPORT SUMMARY
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. GAP ANALYSIS
2.3. HISTORICAL ANALYSIS
2.4. CURRENT MARKET TRENDS
2.5. PIPELINE ANALYSIS
2.6. PATENT ANALYSIS
2.7. ANALYST INSIGHT
2.7.1. KEY FINDINGS
2.7.2. RECOMMENDATION
2.7.3. CONCLUSION
2.8. REGULATION
2.8.1. REGULATIONS ON TAX LAWS
2.8.1.1.1. UNITED STATES
2.8.1.1.2. EUROPEAN UNION
2.8.1.1.3. CHINA
2.8.1.1.4. INDIA
2.8.2. DRUG & CLINICAL TRIAL REGULATIONS
2.8.2.1.1. UNITED STATES
2.8.2.1.2. EUROPEAN UNION
2.8.2.1.3. CHINA
2.8.2.1.4. INDIA
2.8.2.1.5. REST OF THE WORLD
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. DEVELOPMENT IN PROTEOMICS, GENOMICS AND IMAGING SYSTEM HAVE BOOSTED THE CNS BIOMARKER MARKET
3.1.2. POURING INVESTMENT FROM GOVERNMENT AND PRIVATE PLAYERS TO DRIVE THE MARKET
3.1.3. RISE IN CANCER, CVD, CHD AND OTHER HEART RELATED DISEASES ACROSS THE GLOBE
3.1.4. FAVORABLE GOVERNMENT POLICIES AND REGULATIONS IS EXPECTED TO DRIVE THE MARKET
3.1.5. RESEARCH & DEVELOPMENT AND SUCCESSFUL CLINICAL TRIALS OF BIOMARKERS ARE DRIVING THE MARKET
3.1.6. FDA NOD TO CNS BIOMARKER DRUGS ARE BOOSTING THE MARKET
3.2. RESTRAINT
3.2.1. HIGH COST OF GLOBAL CNS BIOMARKER TEST & DIAGNOSTICS IS A CONCERN FOR THE MARKET
3.2.2. REIMBURSEMENT POLICIES MAY AFFECT THE GROWTH OF THE MARKET
3.3. OPPORTUNITY
3.3.1. UNTAPPED APAC REGION HAVE HUGE OPPORTUNITY FOR GLOBAL CNS BIOMARKER MARKET
3.3.2. R&D INVESTMENT AND FAVORABLE GOVERNMENT POLICIES ARE DRIVING THE MARKET
PARENT MARKET ANALYSIS
MARKET SEGMENTATION
5.1. GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY APPLICATION 2014-2020,($ MILLIONS)
5.1.1. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET RESEARCH AND ANALYSIS, 2015-2020, ($ MILLIONS)
5.1.2. GLOBAL MEDICAL MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.3. GLOBAL PERSONALIZED MEDICINE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.4. GLOBAL DISEASE RISK ASSESSMENT MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.5. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.6. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2. GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY TYPE 2014-2020, ($ MILLIONS)
5.2.1. GLOBAL SAFETY BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.2. GLOBAL EFFICACY BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.2.1. GLOBAL PHARMACODYNAMIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.2.2. GLOBAL PREDICTIVE BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.2.3. GLOBAL PROGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.3. GLOBAL VALIDATION BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3. GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY END USER, 2014-2020, ($ MILLIONS)
5.3.1. GLOBAL DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.2. GLOBAL EYE CLINICS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.3. GLOBAL HOSPITAL MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.4. GLOBAL PATIENTS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.5. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
COMPETITIVE LANDSCAPE
6.1. MARKET SHARE ANALYSIS
6.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
7.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.1. UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.2. CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2. EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.1. WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.2. ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3. ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.1. INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.2. CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.3. JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.4. ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANY PROFILES
8.1. ABASTAR MDX INC
8.1.1. INTRODUCTION
8.1.2. ABASTAR MDC PRODUCT PORTFOLIO
8.1.3. ABASTAR MDC RECENT ACTIVITIES
8.1.4. ABASTAR MDC SWOT ANALYSIS
8.2. THERMO FISHER SCIENTIFIC
8.2.1. INTRODUCTION
8.2.2. THERMOSCIENTIFIC PRODUCT PORTFOLIO
8.2.3. THERMOSCIENTIFIC RECENT ACTIVITIES
8.2.4. THERMOSCIENTIFIC SWOT ANALYSIS
8.3. ABIANT INC
8.3.1. INTRODUCTION
8.3.2. ABIANT INC PRODUCT PORTFOLIO
8.3.3. ABIANT INC RECENT ACTIVITIES
8.3.4. ABIANT INC SWOT ANALYSIS
8.3.5.
8.4. AVACTA GROUP PLC
8.4.1. INTRODUCTION
8.4.2. AVACTA GROUP PLC PRODUCT PORTFOLIO
8.4.3. AVACTA GROUP PLC RECENT ACTIVITIES
8.4.4. AVACTA GROUP PLC SWOT ANALYSIS
8.5. MERC & CO. INC
8.5.1. INTRODUCTION
8.5.2. MERC & CO. INC PRODUCT PORTFOLIO
8.5.3. MERC & CO. INC RECENT ACTIVITIES
8.5.4. MERC & CO. INC SWOT ANALYSIS
8.6. AVID RADIOPHARMACEUTICALS INC
8.6.1. INTRODUCTION
8.6.2. AVID RADIOPHARMACEUTICALS PRODUCT PORTFOLIO
8.6.3. AVID RADIOPHARMACEUTICALS RECENT ACTIVITIES
8.6.4. AVID RADIOPHARMACEUTICALS SWOT ANALYSIS
8.7. BANYAN BIOMARKERS
8.7.1. INTRODUCTION
8.7.2. BANYAN BIOMARKERS PRODUCT PORTFOLIO
8.7.3. BANYAN BIOMARKERS RECENT ACTIVITIES
8.7.4. BANYAN BIOMARKERS SWOT ANALYSIS
8.8. DIAGENIC ASA
8.8.1. INTRODUCTION
8.8.2. DIAGENIC ASA PRODUCT PORTFOLIO
8.8.3. DIAGENIC ASA RECENT ACTIVITIES
8.8.4. DIAGENIC ASA SWOT ANALYSIS
8.9. GREAT LAKES NEUROTECHNOLOGIES
8.9.1. INTRODUCTION
8.9.2. GREAT LAKES NEUROTECHNOLOGIES PRODUCT PORTFOLIO
8.9.3. GREAT LAKES NEUROTECHNOLOGIES RECENT ACTIVITIES
8.9.4. GREAT LAKES NEUROTECHNOLOGIES SWOT ANALYSIS
8.10. INNOGENETICS BIOLOGICALS
8.10.1. INTRODUCTION
8.10.2. INNOGENETICS BIOLOGICALS PRODUCT PORTFOLIO
8.10.3. INNOGENETICS BIOLOGICALS RECENT ACTIVITIES
8.10.4. INNOGENETICS BIOLOGICALS SWOT ANALYSIS
8.11. GENENEWS LTD
8.11.1. INTRODUCTION
8.11.2. GENENEWS LTD PRODUCT PORTFOLIO
8.11.3. GENENEWS LTD RECENT ACTIVITIES
8.11.4. GENENEWS LTD SWOT ANALYSIS
8.12. ENZO BIOCHEM INC
8.12.1. INTRODUCTION
8.12.2. ENZO BIOCHEM INC PRODUCT PORTFOLIO
8.12.3. ENZO BIOCHEM INC RECENT ACTIVITIES
8.12.4. ENZO BIOCHEM INC SWOT ANALYSIS
8.13. ACUMEN PHARMACEUTICALS INC
8.13.1. INTRODUCTION
8.13.2. ACUMEN PHARMACEUTICALS INC PRODUCT PORTFOLIO
8.13.3. ACUMEN PHARMACEUTICALS INC RECENT ACTIVITIES
8.13.4. ACUMEN PHARMACEUTICALS INC SWOT ANALYSIS
8.14. ADLYFE INC
8.14.1. INTRODUCTION
8.14.2. ADLYFE INC PRODUCT PORTFOLIO
8.14.3. ADLYFE INC RECENT ACTIVITIES
8.14.4. ADLYFE INC SWOT ANALYSIS
8.15. ALSERES PHARMACEUTICALS INC
8.15.1. INTRODUCTION
8.15.2. ALSERES PHARMACEUTICALS INC PRODUCT PORTFOLIO
8.15.3. ALSERES PHARMACEUTICALS INC RECENT ACTIVITIES
8.15.4. ALSERES PHARMACEUTICALS INC SWOT ANALYSIS
8.16. APITOPE INTERNATIONAL
8.16.1. INTRODUCTION
8.16.2. APITOPE INTERNATIONAL PRODUCT PORTFOLIO
8.16.3. APITOPE INTERNATIONAL RECENT ACTIVITIES
8.16.4. APITOPE INTERNATIONAL SWOT ANALYSIS
8.17. APOSENSE
8.17.1. INTRODUCTION
8.17.2. APOSENSE PRODUCT PORTFOLIO
8.17.3. APOSENSE RECENT ACTIVITIES
8.17.4. APOSENSE SWOT ANALYSIS
8.18. APPLIED NEUROSOLUTIONS INC
8.18.1. INTRODUCTION
8.18.2. APPLIED NEUROSOLUTIONS INC PRODUCT PORTFOLIO
8.18.3. APPLIED NEUROSOLUTIONS INC RECENT ACTIVITIES
8.18.4. APPLIED NEUROSOLUTIONS INC SWOT ANALYSIS
8.19. METABOLON INC
8.19.1. INTRODUCTION
8.19.2. METABOLON INC PRODUCT PORTFOLIO
8.19.3. METABOLON INC RECENT ACTIVITIES
8.19.4. METABOLON INC SWOT ANALYSIS
8.20. INNOVATIVE NEUROTECHNOLOGIES INC
8.20.1. INTRODUCTION
8.20.2. INNOVATIVE NEUROTECHNOLOGIES PRODUCT PORTFOLIO
8.20.3. INNOVATIVE NEUROTECHNOLOGIES RECENT ACTIVITIES
8.20.4. INNOVATIVE NEUROTECHNOLOGIES SWOT ANALYSIS
1.1. RESEARCH METHODS AND TOOLS
1.2. MARKET BREAKDOWN
1.2.1. BY SEGMENTS
1.2.2. BY GEOGRAPHY
1.2.3. BY STAKEHOLDERS
1.2.4. EXCEPTIONS
MARKET OVERVIEW AND INSIGHTS
2.1. DEFINITION
2.2. GAP ANALYSIS
2.3. HISTORICAL ANALYSIS
2.4. CURRENT MARKET TRENDS
2.5. PIPELINE ANALYSIS
2.6. PATENT ANALYSIS
2.7. ANALYST INSIGHT
2.7.1. KEY FINDINGS
2.7.2. RECOMMENDATION
2.7.3. CONCLUSION
2.8. REGULATION
2.8.1. REGULATIONS ON TAX LAWS
2.8.1.1.1. UNITED STATES
2.8.1.1.2. EUROPEAN UNION
2.8.1.1.3. CHINA
2.8.1.1.4. INDIA
2.8.2. DRUG & CLINICAL TRIAL REGULATIONS
2.8.2.1.1. UNITED STATES
2.8.2.1.2. EUROPEAN UNION
2.8.2.1.3. CHINA
2.8.2.1.4. INDIA
2.8.2.1.5. REST OF THE WORLD
MARKET DETERMINANT
3.1. MOTIVATORS
3.1.1. DEVELOPMENT IN PROTEOMICS, GENOMICS AND IMAGING SYSTEM HAVE BOOSTED THE CNS BIOMARKER MARKET
3.1.2. POURING INVESTMENT FROM GOVERNMENT AND PRIVATE PLAYERS TO DRIVE THE MARKET
3.1.3. RISE IN CANCER, CVD, CHD AND OTHER HEART RELATED DISEASES ACROSS THE GLOBE
3.1.4. FAVORABLE GOVERNMENT POLICIES AND REGULATIONS IS EXPECTED TO DRIVE THE MARKET
3.1.5. RESEARCH & DEVELOPMENT AND SUCCESSFUL CLINICAL TRIALS OF BIOMARKERS ARE DRIVING THE MARKET
3.1.6. FDA NOD TO CNS BIOMARKER DRUGS ARE BOOSTING THE MARKET
3.2. RESTRAINT
3.2.1. HIGH COST OF GLOBAL CNS BIOMARKER TEST & DIAGNOSTICS IS A CONCERN FOR THE MARKET
3.2.2. REIMBURSEMENT POLICIES MAY AFFECT THE GROWTH OF THE MARKET
3.3. OPPORTUNITY
3.3.1. UNTAPPED APAC REGION HAVE HUGE OPPORTUNITY FOR GLOBAL CNS BIOMARKER MARKET
3.3.2. R&D INVESTMENT AND FAVORABLE GOVERNMENT POLICIES ARE DRIVING THE MARKET
PARENT MARKET ANALYSIS
MARKET SEGMENTATION
5.1. GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY APPLICATION 2014-2020,($ MILLIONS)
5.1.1. GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET RESEARCH AND ANALYSIS, 2015-2020, ($ MILLIONS)
5.1.2. GLOBAL MEDICAL MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.3. GLOBAL PERSONALIZED MEDICINE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.4. GLOBAL DISEASE RISK ASSESSMENT MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.5. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.1.6. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2. GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY TYPE 2014-2020, ($ MILLIONS)
5.2.1. GLOBAL SAFETY BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.2. GLOBAL EFFICACY BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.2.1. GLOBAL PHARMACODYNAMIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.2.2. GLOBAL PREDICTIVE BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.2.3. GLOBAL PROGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.2.3. GLOBAL VALIDATION BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3. GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY END USER, 2014-2020, ($ MILLIONS)
5.3.1. GLOBAL DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.2. GLOBAL EYE CLINICS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.3. GLOBAL HOSPITAL MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.4. GLOBAL PATIENTS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
5.3.5. GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
COMPETITIVE LANDSCAPE
6.1. MARKET SHARE ANALYSIS
6.2. KEY COMPANY ANALYSIS
REGIONAL ANALYSIS
7.1. NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.1. UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
7.1.2. CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2. EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.1. WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.2.2. ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3. ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.1. INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.2. CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.3. JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
7.3.4. ROAPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
7.4. REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020
COMPANY PROFILES
8.1. ABASTAR MDX INC
8.1.1. INTRODUCTION
8.1.2. ABASTAR MDC PRODUCT PORTFOLIO
8.1.3. ABASTAR MDC RECENT ACTIVITIES
8.1.4. ABASTAR MDC SWOT ANALYSIS
8.2. THERMO FISHER SCIENTIFIC
8.2.1. INTRODUCTION
8.2.2. THERMOSCIENTIFIC PRODUCT PORTFOLIO
8.2.3. THERMOSCIENTIFIC RECENT ACTIVITIES
8.2.4. THERMOSCIENTIFIC SWOT ANALYSIS
8.3. ABIANT INC
8.3.1. INTRODUCTION
8.3.2. ABIANT INC PRODUCT PORTFOLIO
8.3.3. ABIANT INC RECENT ACTIVITIES
8.3.4. ABIANT INC SWOT ANALYSIS
8.3.5.
8.4. AVACTA GROUP PLC
8.4.1. INTRODUCTION
8.4.2. AVACTA GROUP PLC PRODUCT PORTFOLIO
8.4.3. AVACTA GROUP PLC RECENT ACTIVITIES
8.4.4. AVACTA GROUP PLC SWOT ANALYSIS
8.5. MERC & CO. INC
8.5.1. INTRODUCTION
8.5.2. MERC & CO. INC PRODUCT PORTFOLIO
8.5.3. MERC & CO. INC RECENT ACTIVITIES
8.5.4. MERC & CO. INC SWOT ANALYSIS
8.6. AVID RADIOPHARMACEUTICALS INC
8.6.1. INTRODUCTION
8.6.2. AVID RADIOPHARMACEUTICALS PRODUCT PORTFOLIO
8.6.3. AVID RADIOPHARMACEUTICALS RECENT ACTIVITIES
8.6.4. AVID RADIOPHARMACEUTICALS SWOT ANALYSIS
8.7. BANYAN BIOMARKERS
8.7.1. INTRODUCTION
8.7.2. BANYAN BIOMARKERS PRODUCT PORTFOLIO
8.7.3. BANYAN BIOMARKERS RECENT ACTIVITIES
8.7.4. BANYAN BIOMARKERS SWOT ANALYSIS
8.8. DIAGENIC ASA
8.8.1. INTRODUCTION
8.8.2. DIAGENIC ASA PRODUCT PORTFOLIO
8.8.3. DIAGENIC ASA RECENT ACTIVITIES
8.8.4. DIAGENIC ASA SWOT ANALYSIS
8.9. GREAT LAKES NEUROTECHNOLOGIES
8.9.1. INTRODUCTION
8.9.2. GREAT LAKES NEUROTECHNOLOGIES PRODUCT PORTFOLIO
8.9.3. GREAT LAKES NEUROTECHNOLOGIES RECENT ACTIVITIES
8.9.4. GREAT LAKES NEUROTECHNOLOGIES SWOT ANALYSIS
8.10. INNOGENETICS BIOLOGICALS
8.10.1. INTRODUCTION
8.10.2. INNOGENETICS BIOLOGICALS PRODUCT PORTFOLIO
8.10.3. INNOGENETICS BIOLOGICALS RECENT ACTIVITIES
8.10.4. INNOGENETICS BIOLOGICALS SWOT ANALYSIS
8.11. GENENEWS LTD
8.11.1. INTRODUCTION
8.11.2. GENENEWS LTD PRODUCT PORTFOLIO
8.11.3. GENENEWS LTD RECENT ACTIVITIES
8.11.4. GENENEWS LTD SWOT ANALYSIS
8.12. ENZO BIOCHEM INC
8.12.1. INTRODUCTION
8.12.2. ENZO BIOCHEM INC PRODUCT PORTFOLIO
8.12.3. ENZO BIOCHEM INC RECENT ACTIVITIES
8.12.4. ENZO BIOCHEM INC SWOT ANALYSIS
8.13. ACUMEN PHARMACEUTICALS INC
8.13.1. INTRODUCTION
8.13.2. ACUMEN PHARMACEUTICALS INC PRODUCT PORTFOLIO
8.13.3. ACUMEN PHARMACEUTICALS INC RECENT ACTIVITIES
8.13.4. ACUMEN PHARMACEUTICALS INC SWOT ANALYSIS
8.14. ADLYFE INC
8.14.1. INTRODUCTION
8.14.2. ADLYFE INC PRODUCT PORTFOLIO
8.14.3. ADLYFE INC RECENT ACTIVITIES
8.14.4. ADLYFE INC SWOT ANALYSIS
8.15. ALSERES PHARMACEUTICALS INC
8.15.1. INTRODUCTION
8.15.2. ALSERES PHARMACEUTICALS INC PRODUCT PORTFOLIO
8.15.3. ALSERES PHARMACEUTICALS INC RECENT ACTIVITIES
8.15.4. ALSERES PHARMACEUTICALS INC SWOT ANALYSIS
8.16. APITOPE INTERNATIONAL
8.16.1. INTRODUCTION
8.16.2. APITOPE INTERNATIONAL PRODUCT PORTFOLIO
8.16.3. APITOPE INTERNATIONAL RECENT ACTIVITIES
8.16.4. APITOPE INTERNATIONAL SWOT ANALYSIS
8.17. APOSENSE
8.17.1. INTRODUCTION
8.17.2. APOSENSE PRODUCT PORTFOLIO
8.17.3. APOSENSE RECENT ACTIVITIES
8.17.4. APOSENSE SWOT ANALYSIS
8.18. APPLIED NEUROSOLUTIONS INC
8.18.1. INTRODUCTION
8.18.2. APPLIED NEUROSOLUTIONS INC PRODUCT PORTFOLIO
8.18.3. APPLIED NEUROSOLUTIONS INC RECENT ACTIVITIES
8.18.4. APPLIED NEUROSOLUTIONS INC SWOT ANALYSIS
8.19. METABOLON INC
8.19.1. INTRODUCTION
8.19.2. METABOLON INC PRODUCT PORTFOLIO
8.19.3. METABOLON INC RECENT ACTIVITIES
8.19.4. METABOLON INC SWOT ANALYSIS
8.20. INNOVATIVE NEUROTECHNOLOGIES INC
8.20.1. INTRODUCTION
8.20.2. INNOVATIVE NEUROTECHNOLOGIES PRODUCT PORTFOLIO
8.20.3. INNOVATIVE NEUROTECHNOLOGIES RECENT ACTIVITIES
8.20.4. INNOVATIVE NEUROTECHNOLOGIES SWOT ANALYSIS
LIST OF TABLES
TABLE # 1 GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY APPLICATION 2014-2020,($ MILLIONS)
TABLE # 2 GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET RESEARCH AND ANALYSIS, 2015-2020, ($ MILLIONS)
TABLE # 3 GLOBAL MEDICAL MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 4 GLOBAL PERSONALIZED MEDICINE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 5 GLOBAL DISEASE RISK ASSESSMENT MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 6 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 7 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 8 GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY TYPE 2014-2020, ($ MILLIONS)
TABLE # 9 GLOBAL SAFETY BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 10 GLOBAL EFFICACY BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 11 GLOBAL PHARMACODYNAMIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 12 GLOBAL PREDICTIVE BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 13 GLOBAL PROGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 14 GLOBAL VALIDATION BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 15 GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY END USER, 2014-2020, ($ MILLIONS)
TABLE # 16 GLOBAL DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 17 GLOBAL EYE CLINICS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 18 GLOBAL HOSPITAL MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 19 GLOBAL PATIENTS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 20 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 1 GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY APPLICATION 2014-2020,($ MILLIONS)
TABLE # 2 GLOBAL DRUG DISCOVERY & DEVELOPMENT MARKET RESEARCH AND ANALYSIS, 2015-2020, ($ MILLIONS)
TABLE # 3 GLOBAL MEDICAL MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 4 GLOBAL PERSONALIZED MEDICINE MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 5 GLOBAL DISEASE RISK ASSESSMENT MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 6 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 7 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 8 GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY TYPE 2014-2020, ($ MILLIONS)
TABLE # 9 GLOBAL SAFETY BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 10 GLOBAL EFFICACY BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 11 GLOBAL PHARMACODYNAMIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 12 GLOBAL PREDICTIVE BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 13 GLOBAL PROGNOSTIC BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 14 GLOBAL VALIDATION BIOMARKER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 15 GLOBAL CNS BIOMARKER MARKET RESEARCH AND ANALYSIS, BY END USER, 2014-2020, ($ MILLIONS)
TABLE # 16 GLOBAL DIAGNOSTIC CENTERS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 17 GLOBAL EYE CLINICS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 18 GLOBAL HOSPITAL MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 19 GLOBAL PATIENTS MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
TABLE # 20 GLOBAL OTHER MARKET RESEARCH AND ANALYSIS, 2014-2020, ($ MILLIONS)
LIST OF FIGURES
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 5 WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 6 ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 7 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 8 INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 9 CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 10 JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 11 ROPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 12 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020 TABLES
COMPANIES MENTIONED
1. ABASTAR MDX INC
2. THERMO FISHER SCIENTIFIC
3. ABIANT INC
4. AVACTA GROUP PLC
5. MERC & CO. INC
6. AVID RADIOPHARMACEUTICALS INC
7. BANYAN BIOMARKERS
8. DIAGENIC ASA
9. GREAT LAKES NEUROTECHNOLOGIES
10. INNOGENETICS BIOLOGICALS
11. GENENEWS LTD
12. ENZO BIOCHEM INC
13. ACUMEN PHARMACEUTICALS INC
14. ADLYFE INC
15. ALSERES PHARMACEUTICALS INC
16. APITOPE INTERNATIONAL
17. APOSENSE
18. APPLIED NEUROSOLUTIONS INC
19. METABOLON INC
20. INNOVATIVE NEUROTECHNOLOGIES INC
FIGURE # 1 NORTH AMERICAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 2 UNITED STATES MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 3 CANADA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 4 EUROPEAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 5 WESTERN EUROPE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 6 ROE MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 7 ASIA PACIFIC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 8 INDIA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 9 CHINA MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 10 JAPAN MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 11 ROPAC MARKET RESEARCH AND ANALYSIS, 2014-2020
FIGURE # 12 REST OF THE WORLD MARKET RESEARCH AND ANALYSIS, 2014-2020 TABLES
COMPANIES MENTIONED
1. ABASTAR MDX INC
2. THERMO FISHER SCIENTIFIC
3. ABIANT INC
4. AVACTA GROUP PLC
5. MERC & CO. INC
6. AVID RADIOPHARMACEUTICALS INC
7. BANYAN BIOMARKERS
8. DIAGENIC ASA
9. GREAT LAKES NEUROTECHNOLOGIES
10. INNOGENETICS BIOLOGICALS
11. GENENEWS LTD
12. ENZO BIOCHEM INC
13. ACUMEN PHARMACEUTICALS INC
14. ADLYFE INC
15. ALSERES PHARMACEUTICALS INC
16. APITOPE INTERNATIONAL
17. APOSENSE
18. APPLIED NEUROSOLUTIONS INC
19. METABOLON INC
20. INNOVATIVE NEUROTECHNOLOGIES INC
